Abstract
Pomalidomide is the third-generation immunomodulatory imide drug (IMiD) derived from thalidomide, approved for the treatment of multiple myeloma (MM). The exact mechanisms of action of pomalidomide are unclear; however, given the structural similarities between pomalidomide and the second-generation IMiD lenalidomide, it is postulated that the two IMiDs share common effects. Pomalidomide is more potent than lenalidomide and is efficacious in lenalidomide-resistant cases. However, pomalidomide-resistant cases have been observed. This chapter will review data from notable clinical trials of pomalidomide and explore the potential mechanisms of pomalidomide action and resistance.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Abbreviations
- EMA:
-
European Medicines Agency
- FDA:
-
US Food and Drug Administration
- IMiD:
-
Immunomodulatory imide drug
- mRNA:
-
Messenger RNA
- NF-κβ:
-
Nuclear factor-kappa B
- ORR:
-
Overall response rate
- OS:
-
Overall survival
- PFS:
-
Progression-free survival
- PI:
-
Proteasome inhibitor
- RRMM:
-
Relapsed/refractory multiple myeloma
- TGA:
-
Therapeutic Goods Administration
References
PubChem Compound Summary for CID 134780, Pomalidomide; [cited 2020 Sept. 24]. [Internet]. PubChem [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information. 2004. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Pomalidomide.
Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055–66.
Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123(12):1826–32.
Leleu X, Attal M, Arnulf B, Moreau P, Traulle C, Marit G, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02. Blood. 2013;121(11):1968–75.
Sehgal K, Das R, Zhang L, Verma R, Deng Y, Kocoglu M, et al. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood. 2015;125(26):4042–51.
Baz RC, Martin TG 3rd, Lin HY, Zhao X, Shain KH, Cho HJ, et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016;127(21):2561–8.
Richardson PG, Hofmeister CC, Raje NS, Siegel DS, Lonial S, Laubach J, et al. Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma. Leukemia. 2018;32(10):2305.
Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017;130(8):974–81.
Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, et al. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019;6(9):e459–e69.
Chang X, Zhu Y, Shi C, Stewart AK. Mechanism of immunomodulatory drugs’ action in the treatment of multiple myeloma. Acta Biochim Biophys Sin. 2014;46(3):240–53.
Li S, Pal R, Monaghan SA, Schafer P, Ouyang H, Mapara M, et al. IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM. Blood. 2011;117(19):5157–65.
Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother. 2009;58(7):1033–45.
Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26(11):2326–35.
Steven R, Schuster KMK, Zhu YX, Braggio E, Shi C-X, Bruins L, Schmidt J, Ahmann G, Kumar SK, Rajkumar SV, Mikhael JR, Roy V, LaPlant BR, Laumann K, Barlogie B, Shaughnessy JD, Fonseca R, Bergsagel L, Lacy MQ, Stewart K. Cereblon expression predicts response, progression free and overall survival after pomalidomide and dexamethasone therapy in multiple myeloma. Blood. 2012;120(21)
Acknowledgment
Many thanks to the reviewers of this manuscript and my coeditor Steven Trieu. This work was supported by NSW Pathology and the SWSLHD mid-career grant.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Yeung, A.JT., Ling, S.C. (2021). Pomalidomide. In: Ling, S.C., Trieu, S. (eds) Resistance to Targeted Therapies in Multiple Myeloma. Resistance to Targeted Anti-Cancer Therapeutics, vol 22. Springer, Cham. https://doi.org/10.1007/978-3-030-73440-4_3
Download citation
DOI: https://doi.org/10.1007/978-3-030-73440-4_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-73439-8
Online ISBN: 978-3-030-73440-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)